Melatonin prolonged-release (Slenyto®) not recommended for use within NHS Scotland for treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

Slenyto® compared with placebo, increased total sleep time and sleep onset latency in children who had an insufficient response to sleep hygiene measures. However, the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Source:

Scottish Medicines Consortium